Prospect: Informaţii pentru utilizator Tavanic i.v. 500 mg soluţie perfuzabilă Levofloxacină Citiţi cu atenţie şi în în
![Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial - The Lancet Oncology Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/046c525d-65cd-4490-8082-4091bd898c6f/gr1.jpg)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial - The Lancet Oncology
![Levofloxacin resistance rate of E. coli according to various risk factors | Download Scientific Diagram Levofloxacin resistance rate of E. coli according to various risk factors | Download Scientific Diagram](https://www.researchgate.net/publication/51651935/figure/tbl3/AS:203356120326168@1425495285834/Levofloxacin-resistance-rate-of-E-coli-according-to-various-risk-factors.png)